4WEB Medical Launches Hyperlordotic Lateral Implant Portfolio

Innovation and new product launches fuel continued revenue growth

4WEB Medical, an orthopedic device company focused on developing innovative implants with an Advanced Structural Design utilizing its proprietary Truss Implant Technology, announced today the company’s launch of a comprehensive array of hyperlordotic lateral implants.

4WEB Medical advises that the first procedure was performed by Brad Prybis, MD, a surgeon at Tanner Medical Center in Carollton, GA.

“The application of 4WEB’s Truss Implant Technology within the lateral spine space has positively impacted my practice over the years,” said Dr. Prybis. “The new hyperlordotic implant offering, combined with an already comprehensive lateral portfolio, expands my treatment options for patients who need more extensive sagittal balance correction.”

The newest addition to the Lateral Spine Truss System (LSTS) will include implants with 18°, 24°, and 30° lordotic angles to be used for complex spine correction in anterior longitudinal release procedures. These implants, combined with 4WEB’s Lumbar Spine Plating Solution, allow for more cost-effective treatment options and reduce the need for larger, more invasive posterior corrective procedures. The company’s lateral access portfolio also includes procedural-based solutions developed for Direct Lateral, Anterior-to-Psoas (ATP), and Prone Lateral approaches to the lumbar spine.

“The launch of the hyperlordotic lateral implants is the latest in a string of high impact product launches that have fueled record growth for the company,” said Jim Bruty, Sr. Vice President of Sales and Marketing. Revenue from the Stand-Alone Anterior Lumbar Spine Truss System (ASTS-SA), Stand-Alone Cervical Spine Truss System™ (CSTS-SA), and Lumbar Spine Plating Solution (LSTS-PS) were primary drivers of core spine revenue growth in 2021. “Largely attributed to these new product launches, 4WEB finished 2021 with nearly 30% year-over-year growth.”

Beyond the Hyperlordotic LSTS launch, 4WEB has plans for three additional significant product launches in 2022 that will further sustain the company’s rapid growth trajectory.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version